

The 4th Biomedical Innovation Workshop 2012
Dec. 14, 2012

**The Discussion Guide
for
Health and Innovation
Toward Realization of Innovation in Clinical Practice**

Chiaki Sato, Ph. D, LL.M.

The Policy Alternatives Research Institute

The University of Tokyo

Healthcare and Innovation

- Toward Realization of Innovation in Clinical Practice -

The most fundamental and key question: For physicians, what are reasons that undertaking biomedical innovation is important, and what do we stand to gain from pursuing biomedical innovation?

Possible incentive lists for biomedical innovation in clinical arena

- ❑ Desire for treating patients better than past
- ❑ Incentive for getting better research and clinical environment
 - More support for emerging biomedical research fields
 - Focusing on not only on pharmaceuticals but on medical devices and other new products and technologies
 - Securing transparent funding schemes for clinical researches and trials
 - Building efficient regulatory pathways for clinical trials and marketing
 - Delivering reliable clinical knowledge to patients
- ❑ Incentive for attracting human capital in biomedical innovation
 - Payment or reward based on activities for biomedical innovation (service basis and/or quality basis)
 - Life and career pathways for researchers who are involved in biomedical innovation
 - Promoting the role of universities for bridging between seeds of new medical technologies and better clinical practice in proper collaboration with patients and industries

Global Environment

- ❑ Competition among countries with regard to attracting great researchers and medical practitioners

Remaining issues for our next workshops:

- How should we build regulatory ecosystem in better access to new products and therapies?
- How should we make a measurement for value in healthcare?
- How should we make incentive schemes for both the clinical side and non-clinical side for biomedical innovation?
- How should we make better financial schemes for affording biomedical innovation in recent budgetary limitations?
- How should we use medical information with sufficient privacy protection for improvement clinical practice and more personalized medicine?

Source: See, e.g., Council on Biomedical Innovation at the Cabinet Secretariat of Japan, The Strategy for 5 years in Promoting Biomedical Innovation, June, 2012; Ross C. DeVol, Armen Bedroussian, and Benjamin Yeo, The Global Biomedical Industry: Preserving U.S. Leadership, Milken Institute, Sep. 2011; PhRMA, Growth Platform for Economies Around The World, May 2012; The White House, National Bioeconomy Blueprint, Apr. 2012. See also IOM, Roundtable on Value & Science-Driven Health Care Sep. 27, 2012; Engelberg Center for Healthcare Reform at the Brookings Institution, Discussion Guide for New Policy Directions for Biomedical Innovation, Nov. 19, 2012.

Thank you!



Policy
Alternatives
Research
Institute